- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
Global Cancer Test Market (2021 to 2027) - Industry Analysis, Size, Share, Growth, Trends, and Forecast - Theinsightpartners.com
Mar 02, 2021
Asia-Pacific Colorectal Cancer Market is anticipated to reach US$ 4,900.6 Mn in 2027| Business Market Insights
Mar 30, 2021
Europe Neurological Biomarkers Market Insights, Opportunity Analysis, Industry Shares And Forecast 2020-2027
Apr 01, 2021
US Practice Management Systems Market is expected to reach US$ 13,267.85 million by 2030
Nov 30, 2023
US Healthcare Fraud Analytics Market is expected to reach US$ 3483.12 Million by 2027 with CAGR of 27.4%
Jan 18, 2021
US Hemp Derivatives Market Make a Long Term Investment by 2027
Mar 19, 2021
Asia Pacific Cold Plasma Equipment Market Is Growing Strongly Over Time 2019-2027 Prominent Key Players like Neoplas tools GmbH, Plasmatreat GmbH, Adtec., Terraplasma Medical GmbH, Tantec A/S, Europlasma NV, Bovie Medical,
Oct 19, 2020